Tweet
amrn
Everybody jumping on the bandwagon again. Up 16+% since I bot yesterday. Have sell day-order in at today's high 10.68. I'll get back in lower later. Shoot, it's just taking a one-day $3,000 profit and running.
Here's the scoop: Friday, March 16, 11:08 AM Shares of Amarin (AMRN +12.2%) soar after the USPTO updates its transaction history for one of the company's patents to read in a more positive light. At least part of the rise in Amarin's share price can also be attributed to ongoing M&A chatter kicked off earlier this week. Comment! [Healthcare, On the Move]
Thursday, March 15, 12:26 PM Sparking gains in Irish biotech firm Amarin (AMRN +8.6%) is a Leerink Swann note speculating that "patent progress could solidify Amarin as a prime takeout candidate given the blockbuster potential for [heart-drug candidate] AMR-101." The firm had earlier said AMRN was moving toward winning its quest for U.S. patent protection for AMR-101. Comment! [Healthcare, M&A, On the Move]
Friday, March 9, 11:01 AM While the good news for investors of Amarin (AMRN +1.1%) is that development on its experimental heart drug derived from fish oil is churning right along, the bad news is that the USPTO can't keep up with the pace to help the company keep generic versions at bay. Leerink Swann predicts the patent office will eventually grant approval after a lengthy appeals process, as it maintains an Outperformance rating and $25 price target on the biotech firm. 1 Comment [On the Move, Healthcare]
Everybody jumping on the bandwagon again. Up 16+% since I bot yesterday. Have sell day-order in at today's high 10.68. I'll get back in lower later. Shoot, it's just taking a one-day $3,000 profit and running.
Here's the scoop: Friday, March 16, 11:08 AM Shares of Amarin (AMRN +12.2%) soar after the USPTO updates its transaction history for one of the company's patents to read in a more positive light. At least part of the rise in Amarin's share price can also be attributed to ongoing M&A chatter kicked off earlier this week. Comment! [Healthcare, On the Move]
Thursday, March 15, 12:26 PM Sparking gains in Irish biotech firm Amarin (AMRN +8.6%) is a Leerink Swann note speculating that "patent progress could solidify Amarin as a prime takeout candidate given the blockbuster potential for [heart-drug candidate] AMR-101." The firm had earlier said AMRN was moving toward winning its quest for U.S. patent protection for AMR-101. Comment! [Healthcare, M&A, On the Move]
Friday, March 9, 11:01 AM While the good news for investors of Amarin (AMRN +1.1%) is that development on its experimental heart drug derived from fish oil is churning right along, the bad news is that the USPTO can't keep up with the pace to help the company keep generic versions at bay. Leerink Swann predicts the patent office will eventually grant approval after a lengthy appeals process, as it maintains an Outperformance rating and $25 price target on the biotech firm. 1 Comment [On the Move, Healthcare]
Comment